Becton, Dickinson and Company $BDX Stock: Keybank National Association OH Grows Position

Keybank National Association OH lifted its position in Becton, Dickinson and Company (NYSE:BDX – Free Report) by 63.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,594 shares of the medical instruments supplier’s stock after acquiring an additional 8,801 shares during the quarter. Keybank National Association OH’s holdings in Becton, Dickinson and Company were worth $4,044,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Maryland Capital Advisors Inc. boosted its position in Becton, Dickinson and Company by 13,900.0% during the third quarter. Maryland Capital Advisors Inc. now owns 140 shares of the medical instruments supplier’s stock valued at $25,000 after purchasing an additional 139 shares in the last quarter. Trifecta Capital Advisors LLC grew its stake in Becton, Dickinson and Company by 59.0% in the third quarter. Trifecta Capital Advisors LLC now owns 167 shares of the medical instruments supplier’s stock valued at $30,000 after purchasing an additional 62 shares during the last quarter. Meeder Asset Management Inc. grew its stake in Becton, Dickinson and Company by 152.2% in the first quarter. Meeder Asset Management Inc. now owns 169 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 102 shares during the last quarter. Main Street Group LTD bought a new position in Becton, Dickinson and Company in the first quarter worth about $29,000. Finally, Bell Investment Advisors Inc bought a new position in Becton, Dickinson and Company in the second quarter worth about $29,000. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

BDX has been the subject of several recent analyst reports. Royal Bank Of Canada raised their target price on shares of Becton, Dickinson and Company from $190.00 to $225.00 and gave the company a “sector perform” rating in a research note on Friday, November 6th. TD Cowen upped their price objective on shares of Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Zacks Research raised Becton, Dickinson and Company from a “hold” rating to a “strong-buy” rating in a report on Wednesday, October 21st. Weiss Ratings raised shares of Becton, Dickinson and Company from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, November 4th. Finally, Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $175.00 to $200.00 and gave the company a “neutral” rating in a research note on Friday, November 6th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $197.47.

Get Our Latest Research Report on Becton, Dickinson and Company

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Michael Feld sold 165 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the completion of the sale, the executive vice president owned 19,720 shares of the company’s stock, valued at approximately $3,717,022.80. This represents a 0.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas Polen, Jr. sold 2,993 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $210.00, for a total transaction of $628,530.00. Following the sale, the chief executive officer owned 110,163 shares of the company’s stock, valued at approximately $23,134,230. The trade was a 2.65% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,310 shares of company stock valued at $688,650 in the last three months. 0.40% of the stock is currently owned by insiders.

Becton, Dickinson and Company Trading Down 0.0%

Shares of BDX stock opened at $217.95 on Monday. The firm has a market capitalization of $60.05 billion, a P/E ratio of 52.64, a PEG ratio of 3.65 and a beta of 0.22. Becton, Dickinson and Company has a fifty-two week low of $140.11 and a fifty-two week high of $219.78. The stock’s fifty day moving average is $190.90 and its two-hundred day moving average is $170.56. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 earnings per share for the quarter, topping the consensus estimate of $4.07 by $0.08. The business had revenue of $5.27 billion for the quarter, compared to analysts’ expectations of $5.11 billion. Becton, Dickinson and Company had a return on equity of 14.90% and a net margin of 5.66%. The business’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.96 EPS. Research analysts expect that Becton, Dickinson and Company will post 13.21 earnings per share for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, December 31st. Stockholders of record on Thursday, December 10th will be given a dividend of $1.06 per share. This represents a $4.24 annualized dividend and a dividend yield of 1.9%. The ex-dividend date of this dividend is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio is presently 101.45%.

Becton, Dickinson and Company declared that its Board of Directors has authorized a stock repurchase program on Thursday, November 5th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to purchase up to 3.6% of its shares through open market purchases. Stock repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Featured Stories

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.